Testosterone and Raltegravir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Testosterone (testosterone) and Raltegravir (raltegravir). Common drug interactions include neuropathy peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Testosterone and Raltegravir. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Testosterone?

Testosterone has active ingredients of testosterone. It is often used in testosterone. eHealthMe is studying from 6,457 Testosterone users. Check the latest studies of Testosterone.

What is Raltegravir?

Raltegravir has active ingredients of raltegravir. eHealthMe is studying from 5,054 Raltegravir users. Check the latest studies of Raltegravir.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

12 people who take Testosterone and Raltegravir together, and have interactions are studied.

Testosterone and Raltegravir drug interactions.

What are the common drug interactions of Testosterone and Raltegravir, by gender? *:

female:

n/a

male:

Neuropathy peripheral (surface nerve damage)
Chronic kidney disease
Kyphosis (a condition of over-curvature of the thoracic vertebrae (upper back))
Pain
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Diabetic foot infection
Drug intolerance (drug sensitivity)
Drug level decreased
Drug level increased
Erysipelas (bacterial skin infection)

What are the common drug interactions of Testosterone and Raltegravir, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Aortic aneurysm (enlargement of an aortic artery caused by a weakening of the artery wall)
Aortic valve incompetence
Kyphosis (a condition of over-curvature of the thoracic vertebrae (upper back))

30-39:

n/a

40-49:

n/a

50-59:

Neuropathy peripheral (surface nerve damage)
Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
Oral candidiasis (fungal infection of mouth)
Peripheral arterial occlusive disease (reproducible ischemic muscle pain)
Sinusitis (inflammation of sinus)
Transplant rejection (a transplant material is not worked)
Drug resistance (reduction in effectiveness of a drug)
Prostate cancer
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Diabetic foot infection

60+:

n/a

What are the existing conditions these people have? *

Hiv Infection: 10 people, 83.33%
Immunodeficiency Disorders: 4 people, 33.33%
Oral Candidiasis (fungal infection of mouth): 3 people, 25.00%
Dyslipidaemia (abnormal amount of lipids): 3 people, 25.00%
High Blood Pressure: 2 people, 16.67%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 2 people, 16.67%
Transplant Rejection (a transplant material is not worked): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Testosterone and Raltegravir?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously